Several COVID-19 vaccines in phase III, use adenoviral vectors, expressing the S glycoprotein as ChAdOx1 that provided significant results in terms of T-cell response and neutralizing antibodies production (Folegatti et al., 2020); Ad5 vectored COVID-19 vaccine, that demonstrated high tolerability and immunogenicity as reported in trial phase I studies (Zhu F.-C. The gene discussed is ART4; the disease is COVID-19.